Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
Humans
Adolescent
Young Adult
Adult
Middle Aged
Aged
Helicobacter Infections
/ drug therapy
Esomeprazole
/ therapeutic use
Helicobacter pylori
Anti-Bacterial Agents
/ adverse effects
Retrospective Studies
Propensity Score
Proton Pump Inhibitors
/ adverse effects
Amoxicillin
/ therapeutic use
Drug Therapy, Combination
Treatment Outcome
Clarithromycin
/ therapeutic use
Helicobacter pylori
eradication therapy
high-dose dual therapy
risk factors
vonoprazan
Journal
Helicobacter
ISSN: 1523-5378
Titre abrégé: Helicobacter
Pays: England
ID NLM: 9605411
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
25
05
2023
received:
16
03
2023
accepted:
14
06
2023
medline:
6
9
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
ppublish
Résumé
According to the Maastricht VI/Florence consensus report, potassium-competitive acid blockers (P-CAB) may improve Helicobacter pylori eradication treatment. A total of 213 H. pylori treatment-naive patients aged between 18 and 70 years were treated with two regimens. The two regimens are VDT: 20 mg vonoprazan twice a day and 1 g amoxicillin three times daily and EDT: 20 mg esomeprazole four times a day and 750 mg amoxicillin four times daily. On intention-to-treat (ITT) analysis, the eradication rate in VDT group (89.0%; 95% CI 81.7-96.3) was non-inferior to that in EDT group (87.7%; 95% CI 80.1-95.3; p = 0.796). The corresponding per-protocol (PP) eradication rates were 94.1% (95% CI 88.4-99.8) and 92.8% (95% CI 86.7-98.9; p = 1.000), respectively. There were no significant between-group differences with respect to compliance or incidence of AEs. The efficacy and safety of 14-day VDT and EDT were comparable. Therefore, 14-day VDT or EDT may be recommended for the first-line treatment of H. pylori infection.
Sections du résumé
BACKGROUND
BACKGROUND
According to the Maastricht VI/Florence consensus report, potassium-competitive acid blockers (P-CAB) may improve Helicobacter pylori eradication treatment.
MATERIALS AND METHODS
METHODS
A total of 213 H. pylori treatment-naive patients aged between 18 and 70 years were treated with two regimens. The two regimens are VDT: 20 mg vonoprazan twice a day and 1 g amoxicillin three times daily and EDT: 20 mg esomeprazole four times a day and 750 mg amoxicillin four times daily.
RESULTS
RESULTS
On intention-to-treat (ITT) analysis, the eradication rate in VDT group (89.0%; 95% CI 81.7-96.3) was non-inferior to that in EDT group (87.7%; 95% CI 80.1-95.3; p = 0.796). The corresponding per-protocol (PP) eradication rates were 94.1% (95% CI 88.4-99.8) and 92.8% (95% CI 86.7-98.9; p = 1.000), respectively. There were no significant between-group differences with respect to compliance or incidence of AEs.
CONCLUSIONS
CONCLUSIONS
The efficacy and safety of 14-day VDT and EDT were comparable. Therefore, 14-day VDT or EDT may be recommended for the first-line treatment of H. pylori infection.
Substances chimiques
Esomeprazole
N3PA6559FT
Anti-Bacterial Agents
0
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
0
Proton Pump Inhibitors
0
Amoxicillin
804826J2HU
Clarithromycin
H1250JIK0A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13003Subventions
Organisme : National Natural Science Foundation of China
ID : NO.82072253
Organisme : Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission
ID : cstc2021jcyj-msxmX0451
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter. 2017;22(Suppl 1).
Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66:6-30.
Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390:613-624.
Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724-1762.
Guan J-L, Hu Y-L, An P, et al. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: an open-label, multicenter, randomized controlled trial. Pharmacotherapy. 2022;42:224-232.
Zhou L, Lu H, Song Z, et al. Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135:2910.
Unge P, Gad A, Gnarpe H, Olsson J. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol Suppl. 1989;167:49-54.
Zhong Z, Zhang Z, Wang J, et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China. Am J Cancer Res. 2021;11:5027-5037.
Mégraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:1333-1343.
Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut. 1998;43(Suppl 1):S56-S60.
Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003;98:545-550.
Huang C-C, Chen Y-C, Leu H-B, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 2010;105:1705-1709.
Satoh K, Yoshino J, Akamatsu T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol. 2016;51:177-194.
Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27-36.
Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55:409-418.
Graham DY, Lu H, Shiotani A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol. 2021;36:1159-1163.
Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106-114.
Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2020;101:743-751.
Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114:437-445.
Yang J-C, Lin C-J, Wang H-L, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895-905.e5.
Liou J-M, Malfertheiner P, Lee Y-C, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093-2112.
Saito Y, Serizawa H, Kato Y, et al. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol. 2015;21:13548-13554.
Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017;47:1027-1034.
Yu L, Luo L, Long X, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial. Helicobacter. 2019;24:e12596.
Tai W-C, Liang C-M, Kuo C-M, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74:1718-1724.
Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019-1026.
Qian H-S, Li W-J, Dang Y-N, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of helicobacter pylori infection compared with bismuth-containing quadruple therapy. Am J Gastroenterol. 2022;118:627-634.
Hu Y, Xu X, Liu X-S, et al. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022;13:1049908.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155:1372-1382.e17.
Lee JY, Kim N, Nam RH, Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter. 2019;24:e12660.
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022;163(3):608-619.
Suzuki S, Gotoda T, Takano C, et al. Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes. Helicobacter. 2021;26:e12851.
Hu Y, Xu X, Ouyang Y-B, et al. Altered gut microbiota and short-chain fatty acids after vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication. Front Cell Infect Microbiol. 2022;12:881968.